News

A recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of ...
Changing how biopharmas package their products, how regulators review new drugs and how mutated genes are fixed could make ...
CRISPR Therapeutics CRSP and Intellia Therapeutics NTLA are leading developers of therapies that utilize the Nobel ...
We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on Two Natural Cap’s Substack. In this article, we will ...
Accurate and sensitive detection of single nucleotide polymorphism (SNP) holds significant clinical implications, especially in the field of cancer diagnosis. Leveraging its high accuracy and ...
CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the next-gen thrombotic disease asset SRSD107. That drug, Sirius’ lead ...
Shares of gene therapy specialist, CRISPR Therapeutics (CRSP-1.89%) have been beaten down a long way despite some impressive accomplishments. The company already earned approval to sell its first ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.You can reach Elaine on Signal at elaineywchen.70.
In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia.
By Kelly Cloonan. Crispr Therapeutics said it is partnering with Sirius Therapeutics to develop and commercialize SRSD107, a small interfering RNA therapy to treat thromboembolic disorders.
Discover how CRISPR-Cas9 technology is revolutionizing spider silk production with red fluorescent fibers and advancing genetic research.